Introduction
============

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that is complex and progressive, but which is also considered preventable and treatable.[@b1-copd-10-039] The multicomponent nature of COPD is now reflected in several regional and international management guidelines[@b2-copd-10-039],[@b3-copd-10-039] and the recently released *Global Strategy for the Diagnosis, Management and Prevention of COPD* released by GOLD (Global initiative for chronic Obstructive Lung Disease).[@b1-copd-10-039] The GOLD global strategy outlines preferred diagnosis methods for COPD, including evaluation of signs/symptoms, assessment of patient history and past exposure to risk factors, and postbronchodilator spirometric confirmation. Once a COPD diagnosis is confirmed, the GOLD global strategy also recommends a new disease-classification approach that combines symptoms (modified Medical Research Council \[mMRC\] dyspnea grade or COPD Assessment Test) and exacerbation risk (airflow limitation and/or history of exacerbations) to categorize patients into four groups from A (low risk, fewer symptoms) to D (high risk, more symptoms). Pharmacological treatment recommendations for disease management are provided for these groups, ranging from a short-acting anticholinergic and/or short-acting β~2~-agonist for group A patients to combined therapy with an inhaled corticosteroid (ICS) and a long-acting β~2~-agonist (LABA) or long-acting anticholinergic (long-acting muscarinic antagonist \[LAMA\]) for groups C and D (with the possibility of triple therapy with LAMA + ICS/LABA for group D) ([Table 1](#t1-copd-10-039){ref-type="table"}).

Despite the availability of international disease-management guidelines, including those specifically aimed at primary care, COPD often remains underdiagnosed and inappropriately treated.[@b4-copd-10-039]--[@b7-copd-10-039] A large web-based survey in 2011 of primary care physicians (PCPs) across the regions of Asia Pacific, Africa, Eastern Europe, and Latin America showed limited knowledge of COPD guidelines, including underutilization of spirometry for diagnosis of COPD and a general lack of awareness about the significance of exacerbations as an important factor in the management of COPD.[@b8-copd-10-039] Country-specific surveys largely conducted in primary care in Western Europe,[@b5-copd-10-039],[@b6-copd-10-039],[@b9-copd-10-039]--[@b11-copd-10-039] Japan,[@b12-copd-10-039] Mexico,[@b13-copd-10-039] and the USA[@b14-copd-10-039]--[@b16-copd-10-039] have also shown that despite knowledge of guidelines, there is a lack of adherence to guideline recommendations for the treatment of COPD. In the USA, the main barriers to guideline implementation have been reported as low familiarity, low ability or confidence in interpreting recommendations, time constraints, and low outcome expectancy among physicians.[@b15-copd-10-039],[@b16-copd-10-039]

The Continuing to Confront COPD International Physician Survey aimed to describe physician beliefs and behaviors related to COPD risk factors, prognosis, diagnosis, and treatment in a broad sample of PCPs and respiratory specialists across 12 countries worldwide. The objective of this analysis was to describe physicians' knowledge and application of the GOLD global strategy (2011 version) diagnosis and treatment recommendations and compare performance between PCPs and respiratory specialists.

Materials and methods
=====================

Study design and participants
-----------------------------

The Continuing to Confront COPD International Physician Survey was a survey of PCPs and respiratory specialists in 12 countries (Brazil, France, Germany, Italy, Japan, Mexico, the Netherlands, Russia, South Korea, Spain, the UK, and the USA) conducted between January and May 2013. Physicians were required to consult with five or more patients with COPD, emphysema, or chronic bronchitis per month, on average.

The sample of physicians was drawn from in-country databases of professional associations (eg, American Medical Association) and registries with the aim of having a national sample of PCPs and respiratory specialists at a ratio of three to one. This ratio was determined a priority in order to ensure an adequate sample size of each physician type within each country, and was not intended to represent the ratio of these physicians types practicing, or treating patients with COPD in an individual country. Each sample was proportionate to the subnational regions in each country, with the exception of Russia, where the sample was drawn to be roughly representative of the general population of the 12 most developed and populous cities.

Data collection
---------------

A standardized questionnaire was used in all countries to assess physician knowledge of COPD-management guidelines, diagnosis and treatment practices for COPD, and beliefs about COPD risk, natural history, and treatment effectiveness. The standardized questionnaire was translated into local languages in-country and reviewed by an independent translator and a local GlaxoSmithKline clinical advisor for accuracy and cultural relevance. The surveys were conducted online, by telephone, or face to face according to cultural preferences in each country, and were approximately 20 minutes in duration. Where possible, more than one mode of survey methodology was offered to accommodate the preferences of the physicians and to minimize the rate of refusal ([Table 2](#t2-copd-10-039){ref-type="table"}). Modest payments to physicians for their time completing the survey were permitted in line with country regulations. For quality-control purposes, a minimum of 10% of interviews (all sampling methods) were validated by recontact or review of recorded interviews.

The sampling and screening process identified 1,307 physicians who agreed to be interviewed, comprising 200 physicians from the USA and approximately 100 each in the remaining countries ([Table 2](#t2-copd-10-039){ref-type="table"}). The response rate by country ranged from 10% (USA) to 38% (Spain). No association was observed between poor response rates and type of interview technique used (telephone/internet/face to face); countries with the lowest response rates had the highest rates of "noncontact" issues (data not shown). For the total study population, the proportion of PCPs and respiratory specialists was 74% and 26%, respectively. The sample size of 1,307 physicians allowed for a sample precision of ±3.1% for population responses or proportions around 50%.

Outcome definitions
-------------------

The primary objective of the present analysis was to describe physicians' knowledge and application of the GOLD global strategy diagnosis and treatment recommendations and compare performance in applying these guidelines between PCPs and respiratory specialists.

To evaluate physician knowledge about COPD-management guidelines, respondents were queried about whether they were aware of any local/countrywide COPD guidelines, and if so, to what degree these guidelines influenced their everyday treatment practice. Respondents were similarly queried about the GOLD global strategy recommendations and its influence on their practice.

Physician-diagnosis practices were assessed by presenting respondents with a predefined list of diagnostic tests and instructing them to indicate which test(s) they normally conduct in order to establish a diagnosis of COPD (physicians could answer "Yes", "No", or "Test not available" for each test). Respondents were also asked to name the three most important factors in a patient's history when establishing a diagnosis of COPD.

Lastly, physician concordance with prescribing a GOLD global strategy-recommended treatment for different types of COPD patients was evaluated using patient case scenarios (see [Table S1](#SD1-copd-10-039){ref-type="supplementary-material"} for scenario descriptions). Each patient vignette was emblematic of a typical GOLD B, C, or D patient (respondents were not told the patients' GOLD classification as part of the descriptive text). After the scenario was read to the respondents (or displayed online), they were asked to consider which medication(s) they would typically prescribe to such a patient. Respondents could pick one or more of the medication options from a prespecified list that included: 1) short-acting bronchodilator, 2) LAMA, 3) LABA, 4) ICS/LABA combination inhaler, 5) theophylline, 6) roflumilast, 7) triple therapy (LAMA + LABA/ICS fixed-dose combination in two inhaler devices), or 8) oral corticosteroids (chronic use). Respondents could also specify other medications not included in the predefined list; these were reviewed, and those that matched one of the eight prespecified classes of drugs were recoded prior to data analysis. "Concordance" with GOLD strategy for this analysis was defined as selecting a GOLD global strategy first- or second-choice treatment option for the specific type of patient, regardless of whether a medication from the alternative choice was also selected ([Tables 1](#t1-copd-10-039){ref-type="table"} and [S1](#SD1-copd-10-039){ref-type="supplementary-material"}). Respondents could select multiple first- (or second)-choice options and still be considered concordant. The second-choice option "LAMA and LABA" (for GOLD B, C, or D) was not evaluated, because this combination was not included in the prespecified list (no LAMA/LABA fixed-dose combination products were commercially available at the time of survey development). Given the prespecified response categories, we could not ascertain if a physician who selected both 1) LABA and 2) LAMA intended for the products to be used concomitantly or separately. For similar reasons, we did not evaluate the second-choice option of "LAMA and ICS" (for GOLD D). For the GOLD D patient scenario, if a respondent selected either LABA/ICS or LAMA and also selected roflumilast, we assumed that the physician intended to use these in combination, consistent with the indication for roflumilast for use as an add-on therapy to bronchodilator treatment.[@b17-copd-10-039] Respondents were considered "discordant" with GOLD strategy if they 1) selected neither a first- nor second-choice option, 2) selected a first- or second-choice option(s) along with additional nonrecommended therapies, or 3) selected a medication from the alternative choice alone.

Statistical analysis
--------------------

In order to evaluate the hypothesis that PCPs and respiratory specialists vary with regard to key outcomes (utilization of GOLD global strategy-recommended diagnostic tests and guideline-concordant behavior), all countries were combined to obtain a sufficient sample size. While there was some heterogeneity observed across countries, the direction of association was similar (see Supplementary materials for country-specific data). These physician sample data are not weighted because standardized and reliable estimates of the key demographic parameters of the universe of physicians in each country were not readily available. Multivariate logistic regression models, built for each outcome separately, considered physician type as the main exposure and included potential confounding variables. While several potential confounders were considered (knowledge and influence of local/professional guidelines, knowledge and influence of GOLD global strategy, sex, year since graduated medical school, and participation in COPD-based continuing education courses), only awareness of the GOLD global strategy was significantly associated with each outcome and with physician type in univariate analyses. Therefore, all models were adjusted for awareness of the GOLD global strategy and country, and the statistical tests reported herein represent the *P*-value of the physician-type β-coefficient from this final adjusted model.

Results
=======

Demographics of physician sample
--------------------------------

In the global sample from 12 countries, approximately three-quarters of the physicians were male and about half graduated from medical school after 1990, with a similar pattern observed for PCPs and respiratory specialists ([Table 3](#t3-copd-10-039){ref-type="table"}). The proportion of physicians in a multispecialty practice was slightly higher for PCPs (56%) compared with respiratory specialists (48%). Respiratory specialists were more likely to be practicing in urban/city areas (55% versus 37% of PCPs) and to report that they treated COPD patients in an inpatient or hospital-based clinic (33% versus 14% of PCPs). Respiratory specialists had a higher case mix of COPD patients (59% reported at least a third of all patients they treat regularly have COPD versus 8% of PCPs). The majority of physicians had received some continuing education on COPD (88% of respiratory specialists, 71% of PCPs), and most reported using the term "COPD" when discussing the diagnosis with their patients.

Across countries, the proportion of male physicians was greater in Japan and South Korea and lower in Russia compared with the total population; Russia had very few single-specialty practices, and fewer physicians in Japan reported that they received some continuing education on COPD (19% of PCPs; 43% of respiratory specialists). The type, setting, and location of practices showed some variation across countries ([Table 3](#t3-copd-10-039){ref-type="table"}).

Knowledge of guidelines
-----------------------

Across all countries, a high awareness of any professional guidelines for COPD diagnosis/management, including local guidelines, was reported for both PCPs (85%) and respiratory specialists (97%) (*P*\<0.001, [Figure 1A](#f1-copd-10-039){ref-type="fig"}). Results were generally consistent across countries, with the exception of France, where less than half of PCPs reported familiarity with any guidelines. The majority of physicians disclosed that professional guidelines informed their practice (88% of PCPs, 91% of respiratory specialists). Among those who stated that guidelines did not inform their practice (n=123 \[11%\]), the reasons most frequently given were: "I prefer to use my clinical experience" (n=41), "Guidelines do not allow for tailoring treatment to different patient circumstances" (n=35), "Guideline-suggested choice is not available" (n=31), "Guideline is not relevant/disagree with them" (n=27), and "Patient does not prefer/will not adhere to guideline-suggested choice" (n=18).

Respiratory specialists were statistically significantly more likely to report awareness of the GOLD global strategy (58% of PCPs versus 93% of respiratory specialists, *P*\<0.001, [Figure 1B](#f1-copd-10-039){ref-type="fig"}); some variability across countries was observed. Despite lower awareness of the GOLD global strategy, PCPs were more likely to report they had made changes to their management of COPD patients based on these guidelines (61% of PCPs versus 51% of respiratory specialists). Among all physicians who reported that they had made changes to their management as a result of the GOLD global strategy (n=500 \[57%\]), changes included "Using different therapies than those previously used" (59%), "Incorporating lung function measurements" (25%) and "Incorporating the use of the COPD Assessment Test patient-reported outcome instrument" (20%).

Establishing a COPD diagnosis
-----------------------------

Both PCPs and respiratory specialists reported frequently using spirometry testing to establish a COPD diagnosis (100% of respiratory specialists indicated they use spirometry versus 82% of PCPs \[*P*\<0.001\]) ([Table 4](#t5-copd-10-039){ref-type="table"}). An average of 16% of PCPs reported that spirometry was not available in their practice, ranging from 0 to 5% (Russia, UK, Spain, Netherlands, Germany, Brazil) to 46% in France and 82% in Italy ([Table S2](#SD2-copd-10-039){ref-type="supplementary-material"}). Despite the GOLD global strategy recommendation that postbronchodilator spirometry is required for diagnosis and assessment of COPD severity, 22% and 15% of PCPs and respiratory specialists, respectively, indicated that they only use prebronchodilator spirometry. Patient-reported outcomes (eg, dyspnea measure or COPD Assessment Test) were used frequently by both PCPs (67%) and respiratory specialists (81%) as part of assessing COPD. Significantly greater proportions of respiratory specialists than PCPs reported the use of chest X-ray, blood tests/oximetry, bronchodilator responsiveness, computerized tomography or magnetic resonance imaging scans, and patient-reported outcome instruments. Diagnostic practices varied somewhat by country ([Table S2](#SD2-copd-10-039){ref-type="supplementary-material"}).

In response to an open-ended question asking physicians to state up to three top patient factors they consider when establishing a COPD diagnosis, the most frequently reported indicators, as referenced in the GOLD global strategy, were "History of smoking/exposure to passive smoking" (PCPs 73%, respiratory specialists 79%, *P*=0.031), and "Chronic symptoms of airflow obstruction" (PCPs 47%, respiratory specialists 56%, *P*=0.011) ([Table 5](#t6-copd-10-039){ref-type="table"}). This pattern was generally consistent across countries, with the exception of Russia, where "Chronic symptoms of airflow obstruction" followed by "Chronic cough with phlegm" were most frequently reported, and Mexico and Germany, where "History of smoking/exposure to passive smoking" followed by "Occupational exposure to smoke/fumes/dust" were most frequently reported ([Table S3](#SD3-copd-10-039){ref-type="supplementary-material"}).

Application of GOLD global strategy management guidelines using patient scenarios
---------------------------------------------------------------------------------

For the GOLD category B patient scenario, only one in three PCPs (38%) provided a response that was concordant with treatment recommendations, with respiratory specialists statistically significantly more likely to provide a concordant answer (67%, *P*\<0.001, [Figure 2](#f2-copd-10-039){ref-type="fig"}). The most commonly selected concordant option among both types of physicians was LAMA (PCP 22%, respiratory specialists 39%). PCPs were far more likely to report a discordant option of either an ICS-containing regimen or alternative option (short-acting bronchodilator or theophylline alone) than respiratory specialists. Across countries, a similar pattern was observed, with the exceptions of Germany, Italy, and Japan, where the concordance was similar for PCPs and respiratory specialists ([Table S4](#SD4-copd-10-039){ref-type="supplementary-material"}).

In contrast to the GOLD category B patient, PCPs and respiratory specialists performed similarly (40% and 38%, respectively; *P*=0.181) for the GOLD category C patient scenario ([Figure 3](#f3-copd-10-039){ref-type="fig"}). PCPs indicated that they would most likely prescribe ICS/LABA combination inhalers alone (16%), while respiratory specialists commonly selected LAMA alone (13%). The most commonly mentioned discordant option reported by both physician types was triple therapy, which is only recommended for the more severe GOLD D-type patient (PCPs 16%, respiratory specialists 23%). Country-specific data were consistent with the main findings, other than in Spain, Germany, and Japan, where PCPs demonstrated higher levels of concordance versus respiratory specialists, and in Russia respiratory specialists were substantially more concordant than PCPs ([Table S4](#SD4-copd-10-039){ref-type="supplementary-material"}).

For the GOLD category D patient scenario, both physician types performed similarly, with slightly over half providing a concordant response (*P*=0.513, [Figure 4](#f4-copd-10-039){ref-type="fig"}). The most commonly selected concordant option was triple therapy (27% of PCPs and 33% of respiratory specialists); ICS/LABA was also commonly selected. Discordant answers commonly included triple therapy in combinations not recommended by GOLD, including oral corticosteroids (PCPs 7%) and phosphodiesterase 4 inhibitors (respiratory specialists 10%). Countries that were not consistent with the overall pattern of concordance were the USA and Russia (less than 50% of PCPs and respiratory specialists were concordant) and Brazil and Germany (less than 50% of respiratory specialists were concordant) ([Table S4](#SD4-copd-10-039){ref-type="supplementary-material"}).

Discussion
==========

The Continuing to Confront COPD International Physician Survey aimed to describe PCPs' and respiratory specialists' beliefs and behaviors in relation to COPD diagnosis and treatment. Most PCPs and respiratory specialists reported that professional guidelines for COPD diagnosis/management informed their practice, which was widely reflected in the frequent self-reported use of spirometry to establish a diagnosis of COPD. However, with respect to the application of the GOLD global strategy for COPD management, a large proportion of both PCPs and respiratory specialists chose nonconcordant treatments for different patient scenarios.

In the current survey of 12 countries, 85% of PCPs and 97% of respiratory specialists reported an awareness of any professional guidelines for COPD diagnosis/management, including local guidelines, which is higher than that reported in a PCP survey in the USA, which showed that only between a third and a half are highly familiar with GOLD and/or American Thoracic Society/European Respiratory Society guidelines.[@b14-copd-10-039],[@b15-copd-10-039] We observed that significantly fewer PCPs (58%) were familiar with the GOLD global strategy compared with respiratory specialists (93%), similar to findings in previous surveys.[@b8-copd-10-039],[@b10-copd-10-039] This may be related to perceptions that the new GOLD categories have limited application in primary care and the previous suggestion that development of new treatment algorithms should involve the primary care community in order to fully engage their support.[@b18-copd-10-039]

Despite the GOLD global strategy recommendation that spirometry is required to make a clinical diagnosis of COPD, barriers to using spirometry have previously been cited as a lack of access to spirometers, cost of testing/inadequate reimbursement for testing, patient reluctance to have the test, lack of familiarity with recommendation, and time constraints.[@b15-copd-10-039],[@b16-copd-10-039] The self-reported use of spirometry by physicians in the Continuing to Confront COPD International Physician Survey was 80%--100%, which is among the highest reported in similar surveys. In Aisanov et al, 10%--48% of physicians self-reported using spirometry as a COPD diagnostic tool,[@b8-copd-10-039] while other studies show that even when physicians agree on the importance of spirometry, the actual use is only 23%--54%.[@b10-copd-10-039],[@b15-copd-10-039] Self-reported spirometry use in our study is also higher than benchmarks of actual use captured in population-based electronic medical records and health care-claims databases in the USA and UK.[@b19-copd-10-039],[@b20-copd-10-039] In our population, only 16% of PCPs and 0 respiratory specialists reported that they did not have access to spirometry, which may in part explain the higher rate of spirometry use in our survey. However, we did observe a large variation in lack of access by country, ranging from 0 (Russia, UK) up to 46% (France) and 82% (Italy), reported by PCPs. While there are likely some true intercountry differences in the availability of spirometry, some of the variability observed may have been due to differences in understanding of the questionnaire (ie, some respondents interpreted a lack of access as no direct access to spirometry in their clinic, while others interpreted it as no direct access plus no access via a specialist).

While reported diagnostic practices appear largely to reflect guideline recommendations, application of the GOLD global strategy management guidelines was considerably lower. Despite respiratory specialists being significantly more likely to report knowledge of the GOLD global strategy, they did not perform appreciably better than PCPs in providing guideline-concordant answers, possibly suggesting that awareness does not necessarily translate into implementation, given the many variables that factor into the ultimate prescribing decision (eg, physician experience, local formulary, costs, and patient preferences). These findings are similar to those reported in a survey of PCPs and practice nurses in the UK, which showed high awareness levels of national COPD guidelines were not reflected in diagnoses or management strategies when presented with several case scenarios.[@b9-copd-10-039]

However, these concordance findings must be interpreted within the limitations of the data available, as clinical scenarios are incomplete reflections of the complexity of physicians' treatment decision making in the clinic, including the role of constraints faced by physicians with regard to formularies or local guidelines. For example, respiratory specialists in our survey showed a greater reluctance to change their practice or fully adopt guidelines, with many stating they prefer to rely on their clinical experience or feel that guidelines do not adequately account for individual patient symptoms or circumstances, including ability to adhere to recommended medications. Further, our definition of a "concordant response" required a detailed knowledge of both the GOLD patient-severity schema (A--D) and the paired treatment recommendation for each patient type. PCPs in our sample were more likely to report following local guidelines, many of which have yet to adopt the GOLD patient-severity schema or have incorporated different multidimensional indices to define disease severity.[@b21-copd-10-039] As the GOLD global strategy evolves and is further incorporated into local guidelines, it will be of interest to repeat this type of analysis to evaluate improvement in concordance among PCPs and respiratory specialists.

Another limitation of the data that may have affected the percentage reporting a concordant response was that we could not ascertain if a physician who selected the GOLD second-choice options of "LAMA and LABA" or "LAMA and ICS" intended for the products to be used together or as individual therapies. The impact of this limitation was likely to be minimal, however, as such combinations as "LABA and LAMA" were not commercially available in a single device, and concomitant prescriptions of the two medication classes were infrequent at the time of the survey.[@b22-copd-10-039]

The inclusion of both PCPs and respiratory specialists in the Continuing to Confront COPD International Survey provides a unique opportunity to compare physician types with regard to attitudes and behaviors. However, the overall sample from each country was fairly small, making intercountry comparisons challenging statistically. Further, the representativeness of the sample within certain countries may be limited due to low response rates. Such low response rates did not appear attributable to the type of interview technique used in the survey, but were most notable in countries with the greatest issues relating to physician "contact", and this, together with incentivizing respondents with a modest financial reward, may have introduced some responder bias. However, low physician response rates and varied response by country (10% in the USA to 38% in Spain) were broadly consistent with ranges previously reported in published surveys of representative physician samples,[@b10-copd-10-039],[@b23-copd-10-039],[@b24-copd-10-039] and may reflect the two-stage process of this survey (initial contact by post/email that invited the physician to contact the survey research organization for an appointment to complete the questionnaire at their convenience).

In summary, this global survey of PCPs and respiratory specialists showed high awareness of COPD-management guidelines. These guidelines appear to be widely followed by both PCPs and respiratory physicians with regard to diagnostic practices, including reported use of spirometry and frequent consideration of risk factors, including smoking history, symptom presentation, and family history. However, there appears to be less adoption of guidelines when applied to COPD treatment choice, with fewer physicians of both types selecting a suggested GOLD global strategy treatment choice in patient scenarios. Further research is needed to better understand the barriers to implementing treatment recommendations and rationale for alternative treatment choices using a tailored approach for different medical specialties. These data can inform physician-education strategies and public health infrastructure relevant to country-specific/local guidelines with the aim to improve COPD disease management and outcomes.

Supplementary materials
=======================

###### 

Definitions used to identify responses concordant with the GOLD global strategy treatment recommendations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient scenario read to physician                                                                                                                                                                                                                                                                                         GOLD group (answer not provided to respondent)   For a patient like this, what would you typically prescribe? (Multiple responses allowed)   "Concordant" response definition used for this analysis                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  58-year-old female, quit smoking 10 years ago, breathlessness rated as "I walk slower than most people my age", FEV~1~ 65% of predicted, one moderate exacerbation requiring antibiotics in last year, unable to clean her house without becoming fatigued                                                                 B                                                □ Short-acting bronchodilator\                                                              LABA (± SABD or theophylline) or LAMA (± SABD or theophylline) or LABA, LAMA (respondents ticked both options) (± SABD or theophylline)                                                                                             Not evaluated[\*](#tfn16-copd-10-039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                              □ LAMA\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                              □ LABA\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                              □ ICS/LABA combination inhaler\                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                              □ Theophylline\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                              □ Roflumilast\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                              □ Triple therapy (LAMA + LABA/ICS fixed-dose combination in two inhaler devices)\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                              □ Oral corticosteroids (chronic use)                                                                                                                                                                                                                                                                                            

  66-year-old male, active smoker since age 26 years, comorbid high cholesterol and diabetes, breathlessness rated as "only after vigorous exercise", FEV~1~ 40% of predicted, one severe exacerbation requiring hospitalization in last year, primary complaint is cough and sputum                                         C                                                □ Short-acting bronchodilator\                                                              ICS/LABA combination inhaler (± SABD, theophylline, or roflumilast) or LAMA (± SABD, theophylline, or roflumilast) or ICS/LABA combination inhaler, LAMA (respondents ticked both options) (± SABD, theophylline, or roflumilast)   Not evaluated[\*](#tfn16-copd-10-039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                              □ LAMA\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                              □ LABA\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                              □ ICS/LABA combination inhaler\                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                              □ Theophylline\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                              □ Roflumilast\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                              □ Triple therapy (LAMA + LABA/ICS fixed-dose combination in two inhaler devices)\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                              □ Oral corticosteroids (chronic use)                                                                                                                                                                                                                                                                                            

  83-year-old male, active smoker, comorbid coronary artery disease and a history of asthma, breathlessness rated as "I have to stop for breath even when walking on level ground at my own pace", FEV~1~ 32% of predicted, he is coming in for a follow-up after recovering from his second exacerbation in the last year   D                                                □ Short-acting bronchodilator\                                                              ICS/LABA combination inhaler (± SABD or theophylline) or LAMA (± SABD or theophylline) or ICS/LABA combination inhaler, LAMA (respondents ticked both options) (± SABD or theophylline)                                             Triple therapy (± SABD or theophylline) or ICS/LABA combination inhaler + roflumilast (respondents ticked both options) (± SABD or theophylline) or LAMA + roflumilast (respondents ticked both options) (± SABD or theophylline)\
                                                                                                                                                                                                                                                                                                                                                                              □ LAMA\                                                                                                                                                                                                                                                                                                                         LAMA + LABA\
                                                                                                                                                                                                                                                                                                                                                                              □ LABA\                                                                                                                                                                                                                                                                                                                         Not evaluated[\*](#tfn16-copd-10-039){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                              □ ICS/LABA combination inhaler\                                                                                                                                                                                                                                                                                                 ICS + LAMA\
                                                                                                                                                                                                                                                                                                                                                                              □ Theophylline\                                                                                                                                                                                                                                                                                                                 Not evaluated[†](#tfn17-copd-10-039){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                              □ Roflumilast\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                              □ Triple therapy (LAMA + LABA/ICS fixed-dose combination in two inhaler devices)\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                              □ Oral corticosteroids (chronic use)                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

The GOLD-recommended second choice of LAMA and LABA was not provided in the predefined medication list on the survey, as no fixed-dose combination products were commercially available at the time of the survey. Further, it was not possible to ascertain if a physician who selected both of these responses individually intended to use the products together or separately, and thus we assumed that they intended them as separate potential options

the GOLD-recommended second choice of LAMA and ICS was not provided in the predefined medication list on the survey, as no fixed-dose combination products were commercially available at the time of the survey.

**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β~2~-agonist; ICS, inhaled corticosteroid; FEV~1~, forced expiratory volume in 1 second.

###### 

Tests typically used to establish a COPD diagnosis by country and by physician type

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                       USA\    Mexico\   Brazil\   France\   Germany\   Italy\   Spain\   UK\     NL\     Russia\   Japan\   SK\                                                                   
                                       n=200   n=101     n=101     n=100     n=100      n=100    n=100    n=100   n=101   n=100     n=101    n=103                                                                 
  ------------------------------------ ------- --------- --------- --------- ---------- -------- -------- ------- ------- --------- -------- ------- ---- ----- ----- ----- ---- ----- ----- ----- ---- ----- ---- ----
  Spirometry                                                                                                                                                                                                       

   Yes                                 84      100       84        100       93         100      50       100     96      100       15       100     96   100   100   100   96   100   100   100   79   100   83   96

   No                                  5       0         1         0         1          0        4        0       1       0         3        0       0    0     0     0     1    0     0     0     4    0     0    4

   Not available                       11      0         15        0         5          0        46       0       3       0         82       0       4    0     0     0     3    0     0     0     16   0     17   0

  Peak expiratory flow                                                                                                                                                                                             

   Yes                                 63      35        61        54        49         38       77       50      77      88        18       50      59   28    72    16    41   26    38    35    45   71    50   33

   No                                  30      65        15        46        33         58       12       50      16      12        43       50      28   72    28    84    55   74    34    8     27   18    28   63

   Not available                       7       0         24        0         17         4        11       0       7       0         39       0       13   0     0     0     4    0     27    58    27   11    22   4

  Bronchodilator responsiveness                                                                                                                                                                                    

   Yes                                 66      80        69        81        73         77       76       85      88      100       24       85      76   92    76    48    68   74    89    100   53   57    57   78

   No                                  27      20        19        19        21         23       18       15      9       0         41       8       13   8     21    52    27   26    9     0     38   25    33   22

   Not available                       7       0         12        0         5          0        7        0       3       0         35       4       11   0     3     0     5    0     0     0     8    18    11   0

  Oral corticosteroid responsiveness                                                                                                                                                                               

   Yes                                 32      29        55        23        44         35       46       23      52      64        28       42      35   32    37    4     35   11    14    23    36   39    50   7

   No                                  60      71        31        73        49         62       45       77      44      36        55       54      53   68    60    88    62   89    57    12    60   50    39   89

   Not available                       7       0         15        4         7          4        9        0       4       0         16       4       12   0     3     8     3    0     26    62    4    11    9    4

  Chest X-ray                                                                                                                                                                                                      

   Yes                                 84      86        91        92        84         92       58       88      59      80        5        77      91   96    84    84    55   81    99    96    96   100   91   93

   No                                  12      14        7         8         12         8        16       12      15      20        15       8       8    4     13    16    30   15    1     4     3    0     3    7

   Not available                       4       0         3         0         4          0        26       0       27      0         80       15      1    0     3     0     15   4     0     0     1          7    0

  Blood test/oximetry                                                                                                                                                                                              

   Yes                                 38      84        80        73        53         62       30       85      33      84        4        58      53   68    37    40    26   44    92    85    78   86    22   52

   No                                  53      16        13        15        29         35       28       12      24      16        19       27      29   32    49    60    53   48    8     12    12   11    43   44

   Not available                       9       0         7         12        17         4        42       4       43      0         76       15      17   0     13    0     22   7     0     4     10   4     34   4

  CAT/CT/MRI scans                                                                                                                                                                                                 

   Yes                                 15      33        24        42        37         46       19       54      12      48        1        35      12   56    4     16    5    4     39    88    67   79    28   41

   No                                  68      67        47        54        43         42       47       42      49      52        59       46      53   44    72    80    72   89    55    12    8    14    41   52

   Not available                       16      0         29        4         20         12       34       4       39      0         38       15      35   0     24    4     23   7     0     0     25   7     32   7

  Patient-reported outcomes                                                                                                                                                                                        

   Yes                                 75      82        84        92        95         92       65       65      79      84        53       96      55   92    64    60    78   81    59    88    37   71    54   70

   No                                  19      18        13        8         4          8        31       27      16      16        38       4       39   8     32    36    19   19    39    12    53   29    38   26

   Not available                       5       0         3         0         1          0        4        8       5       0         8        0       7    0     4     4     3    0     0     0     10   0     8    4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; NL, the Netherlands; SK, South Korea; PC, primary care; RS, respiratory specialist; CAT, computerized axial tomography; CT, computerized tomography; MRI, magnetic resonance imaging.

###### 

Key indicators for considering a COPD diagnosis: GOLD global strategy by country and by physician type

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                USA\    Mexico\   Brazil\   France\   Germany\   Italy\   Spain\   UK\     NL\     Russia\   Japan\   SK\                                                            
                                                                n=200   n=101     n=101     n=100     n=100      n=100    n=100    n=100   n=101   n=100     n=101    n=103                                                          
  ------------------------------------------------------------- ------- --------- --------- --------- ---------- -------- -------- ------- ------- --------- -------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Chronic symptoms of airflow obstruction (wheezing, dyspnea)                                                                                                                                                                        

   Yes (%)                                                      53      59        15        19        55         69       23       50      20      28        54       81      48   36   51   44   80   85   80   88   41   50   42   59

  Chronic cough with phlegm/sputum                                                                                                                                                                                                   

   Yes (%)                                                      36      41        11        15        44         62       38       50      20      12        61       65      37   24   49   24   59   81   61   73   22   32   32   44

  History of cigarette smoking/exposure to passive smoking                                                                                                                                                                           

   Yes (%)                                                      77      78        88        85        59         73       85       100     84      76        72       62      44   84   85   92   73   78   50   42   95   89   66   85

  Occupational exposure to smoke, fumes, or dust                                                                                                                                                                                     

   Yes (%)                                                      9       6         59        77        8          4        27       15      31      20        30       15      8    4    15   16   8    0    15   12   19   14   24   19

  Family history of emphysema/bronchitis/COPD                                                                                                                                                                                        

   Yes (%)                                                      11      10        4         8         15         12       23       15      11      20        7        4       32   48   19   16   8    0    16   23   4    11   18   0
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Percentages within a physician type will sum to greater than 100%; results from an open-ended question asking physicians to provide the top three most important factors in a patient's history when establishing a COPD diagnosis; no predefined list provided.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; NL, the Netherlands; SK, South Korea; PC, primary care; RS, respiratory specialist.

###### 

Proportion of primary care physicians and respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment options by country

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                     USA\    Mexico\   Brazil\   France\   Germany\   Italy\   Spain\   UK\     NL\     Russia\   Japan\   SK\                                                            
                                                                                                                     n=200   n=101     n=101     n=100     n=100      n=100    n=100    n=100   n=101   n=100     n=101    n=103                                                          
  ------------------------------------------------------------------------------------------------------------------ ------- --------- --------- --------- ---------- -------- -------- ------- ------- --------- -------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  GOLD category B patient[a](#tfn22-copd-10-039){ref-type="table-fn"},[¥](#tfn25-copd-10-039){ref-type="table-fn"}                                                                                                                                                                        

   Concordant (%)                                                                                                    21      67        19        62        29         65       55       81      67      72        50       54      48   84   49   84   51   89   8    27   47   54   28   63

  GOLD category C patient[b](#tfn23-copd-10-039){ref-type="table-fn"},[¥](#tfn25-copd-10-039){ref-type="table-fn"}                                                                                                                                                                        

   Concordant (%)                                                                                                    24      37        32        23        28         31       38       31      49      32        58       54      32   16   48   48   50   52   28   62   59   25   51   48

  GOLD category D patient[c](#tfn24-copd-10-039){ref-type="table-fn"},[†](#tfn26-copd-10-039){ref-type="table-fn"}                                                                                                                                                                        

   Concordant (%)                                                                                                    24      41        63        65        56         38       74       69      68      44        68       69      53   56   72   88   72   85   49   38   62   64   57   52
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Scenario described to physician: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 2, and had one exacerbation in the past year

scenario described to physician: this patient has an mMRC dyspnea scale score of 0, a GOLD airflow-limitation classification of 3, and had one hospitalized exacerbation in the past year

scenario described to physician: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 3, and had two exacerbations in the past year

second-choice option of LAMA and LABA not evaluable

second-choice options of LAMA and LABA or ICS and LAMA not evaluable. Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices.

**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; NL, the Netherlands; SK, South Korea; PC, primary care; RS, respiratory specialist; LAMA, long-acting muscarinic antagonist; LABA, long-acting β~2~-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council.

The survey was conducted by Abt SRBI, a global survey research firm that specializes in health surveys. The authors would like to acknowledge editorial support in the form of draft manuscript development, assembling tables and figures, collating author comments, and copyediting, which was provided by Kate Hollingworth of Continuous Improvement Ltd. The authors would like to further acknowledge the analytical support provided by Joe Maskell. This support was funded by GlaxoSmithKline (GSK).
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![Awareness of (**A**) any professional guidelines and (**B**) 2011 GOLD global strategy guidelines.\
**Note:** *P*\<0.001 comparing total primary care physicians to respiratory specialists, adjusted for country.\
**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; NL, the Netherlands; SK, South Korea.](copd-10-039Fig1){#f1-copd-10-039}

![Proportion of (**A**) primary care physicians (PCPs) and (**B**) respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment options for GOLD category B patient.\
**Notes:** Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. GOLD B scenario: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 2, and had one exacerbation in the past year. \*Respondent independently selected all listed treatment options; does not necessarily reflect the respondent's intention to use these medications simultaneously; ^§^second-choice option of LAMA and LABA not evaluable; ^¥^*P*-value comparing PCPs to respiratory specialists, adjusted for country and awareness of the GOLD global strategy. Individual treatment choices may not add to concordant or discordant response percentage due to rounding.\
**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β~2~-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; NE, not evaluable.](copd-10-039Fig2){#f2-copd-10-039}

![Proportion of (**A**) primary care physicians (PCPs) and (**B**) respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment options for GOLD category C patient.\
**Notes:** Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. GOLD C scenario: this patient has an mMRC dyspnea scale score of 0, a GOLD airflow-limitation classification of 3, and had one hospitalized exacerbation in the past year. \*Respondent independently selected all listed treatment options; does not necessarily reflect the respondent's intention to use these medications simultaneously; ^§^second-choice option of LAMA and LABA not evaluable; ^¥^*P*-value comparing PCPs to respiratory specialists, adjusted for country and awareness of the GOLD global strategy. Individual treatment choices may not add to concordant or discordant response percentage due to rounding.\
**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β~2~-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; NE, not evaluable; PDE; phosphodiesterase.](copd-10-039Fig3){#f3-copd-10-039}

![Proportion of (**A**) primary care specialists (PCPs) and (**B**) respiratory specialists concordant with first- or second- choice GOLD 2011 global strategy treatment options for GOLD category D patient.\
**Notes:** Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. GOLD D scenario: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 3, and had two exacerbations in the past year. \*Respondent independently selected all listed treatment options; does not necessarily reflect the respondent's intention to use these medications simultaneously; ^§^second-choice options of 1) LAMA and LABA and 2) ICS and LAMA not evaluable; ^¥^*P*-value comparing PCPs to respiratory specialists, adjusted for country and awareness of GOLD global strategy. Individual treatment choices may not add to concordant or discordant response percentage due to rounding.\
**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; OCS, oral corticosteroid; LAMA, long-acting muscarinic antagonist; LABA, long-acting β~2~-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; PDE; phosphodiesterase.](copd-10-039Fig4){#f4-copd-10-039}

###### 

Initial pharmacological management of COPD[\*](#tfn1-copd-10-039){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient group   First choice                                                                       Second choice                                                                                                                                                                                                                                                                                                                                                     Alternative choices[\*\*](#tfn2-copd-10-039){ref-type="table-fn"}
  --------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  A               Short-acting anticholinergic RNP or Short-acting β~2~-agonist PRN                  Long-acting anticholinergic or Long-acting β~2~-agonist or Short-acting β~2~-agonist and short-acting anticholinergic                                                                                                                                                                                                                                             Theophylline

  B               Long-acting anticholinergic or Long-acting β~2~-agonist                            Long-acting anticholinergic and long-acting β~2~-agonist                                                                                                                                                                                                                                                                                                          Short-acting β~2~-agonist and/or Short-acting anticholinergic Theophylline

  C               Inhaled corticosteroid + long-acting β~2~-agonist or Long-acting anticholinergic   Long-acting anticholinergic and long-acting β~2~-agonist                                                                                                                                                                                                                                                                                                          Phosphodiesterase-4 inhibitor\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Short-acting β~2~-agonist and/or\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Short-acting anticholinergic Theophylline

  D               Inhaled corticosteroid + long-acting β~2~-agonist or Long-acting anticholinergic   Inhaled corticosteroid and long-acting anticholinergic or Inhaled corticosteroid + long-acting β~2~-agonist and long-acting anticholinergic or Inhaled corticosteroid + long-acting β~2~-agonist and phosphodiesterase-4 inhibitor or Long-acting anticholinergic and long-acting β~2~-agonist or Long-acting anticholinergic and phosphodiesterase-4 inhibitor   Carbocysteine\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Short-acting β~2~-agonist and/or Short-acting anticholinergic Theophylline
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Medications in each box are mentioned in alphabetical order, and thus not necessarily in order of preference;

medications in this column can be used alone or in combination with other options in the first and second columns. From the Global Strategy for Diagnosis, Management and Prevention of COPD 2014, © Global initiative for chronic Obstructive Lung Disease (GOLD), all rights reserved. Available from <http://www.goldcopd.org>.[@b1-copd-10-039]

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PRN, pro re nata (as needed).

###### 

Physician response rate, physician type, and survey method in each country: Continuing to Confront COPD International Survey, 2012--2013

  Country       Physician response rate (%)   Physicians interviewed (n)   PCP/RS (n)   Survey mode
  ------------- ----------------------------- ---------------------------- ------------ -----------------------------------------------------------------------------
  USA           10                            200                          151/49       Telephone
  Mexico        18                            101                          75/26        Internet/telephone
  Brazil        17                            101                          75/26        Internet/telephone
  France        37                            100                          74/26        Internet
  Germany       35                            100                          75/25        Internet
  Italy         21                            100                          74/26        Telephone
  Spain         38                            100                          75/25        Internet/telephone
  UK            31                            100                          75/25        Internet
  Netherlands   21                            101                          74/27        Internet
  Russia        23                            100                          74/26        Internet/face to face
  Japan         13                            101                          73/28        Internet/telephone/face to face[\*](#tfn4-copd-10-039){ref-type="table-fn"}
  South Korea   14                            103                          76/27        Internet/telephone/face to face[\*](#tfn4-copd-10-039){ref-type="table-fn"}
  Total                                       1,307                        971/336      

**Note:**

Face-to-face available only in capital cities, ie, Tokyo and Seoul.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RS, respiratory specialist.

###### 

Demographic characteristics of physicians by country: Continuing to Confront COPD International Survey, 2012--2013

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Total\    USA\    Mexico\   Brazil\   France\   Germany\   Italy\                                    
                                                                 n=1,307   n=200   n=101     n=101     n=100     n=100      n=100                                     
  -------------------------------------------------------------- --------- ------- --------- --------- --------- ---------- -------- ----- ---- ---- ---- ----- ----- -----
  Male                                                           75        77      68        96        75        69         79       62    84   65   65   84    74    81

  Patient setting                                                                                                                                                     

   Outpatient[\*](#tfn6-copd-10-039){ref-type="table-fn"}        86        67      99        80        61        77         77       85    93   50   87   60    100   69

   Inpatient[†](#tfn7-copd-10-039){ref-type="table-fn"}          14        33      1         20        39        23         23       15    7    50   13   40    0     31

  Type of practice                                                                                                                                                    

   Single specialty                                              42        50      69        76        37        65         29       50    49   77   20   40    66    81

   Multispecialty                                                56        48      31        25        61        35         67       50    51   23   77   60    34    15

   Other                                                         1         2       0         0         1         0          4        0     0    0    3    0     0     4

  Graduated medical school                                                                                                                                            

   Before 1980                                                   11        13      9         29        4         12         11       19    12   0    13   0     31    23

   1980s                                                         35        30      35        57        9         23         17       19    46   35   31   32    58    31

   1990s                                                         26        35      36        10        5         39         25       35    19   50   36   52    5     31

   2000 or after                                                 25        21      19        4         75        23         45       27    20   15   11   12    5     12

  Practice location                                                                                                                                                   

   Central city                                                  37        55      18        39        81        85         79       81    31   31   24   52    27    46

   Suburb/small city/town                                        53        43      72        57        15        15         21       19    41   69   52   44    73    54

   Rural area                                                    10        2       11        4         4         0          0        0     28   0    24   4     0     0

  Continuing COPD education, yes                                 71        88      85        96        55        96         39       89    61   73   89   100   88    100

  Percentage of patients seen with COPD                                                                                                                               

   \>50%                                                         2         27      1         18        3         23         3        15    0    19   3    32    1     54

   31%--50%                                                      6         32      3         47        4         27         8        31    2    54   4    32    3     27

   11%--30%                                                      30        34      28        32        44        35         41       50    20   19   40   36    17    4

   ≤10%                                                          63        7       68        2         49        15         48       4     77   8    53   0     80    15

  Use term "COPD" when discussing diagnosis with patients, yes   91        95      99        100       97        100        85       100   88   92   95   100   53    77
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Includes ambulatory care clinic

includes hospital-based clinic.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RS, respiratory specialist.

###### 

Demographic characteristics by country: Continuing to Confront COPD International Survey, 2012--2013 (continued)

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Spain\   UK\     NL\     Russia\   Japan\   SK\                              
                                                                 n=100    n=100   n=101   n=100     n=101    n=103                            
  -------------------------------------------------------------- -------- ------- ------- --------- -------- ------- ---- ---- ---- ---- ---- -----
  Male                                                           81       56      73      76        76       78      41   62   96   86   92   89

  Patient setting                                                                                                                             

   Outpatient[\*](#tfn9-copd-10-039){ref-type="table-fn"}        91       72      93      24        92       85      80   62   51   32   92   96

   Inpatient[†](#tfn10-copd-10-039){ref-type="table-fn"}         9        28      7       76        8        15      20   39   49   68   8    4

  Type of practice                                                                                                                            

   Single specialty                                              57       72      23      16        28       26      1    8    48   54   54   11

   Multispecialty                                                40       24      77      84        70       70      99   92   52   46   41   74

   Other                                                         3        4       0       0         1        4       0    0    0    0    5    15

  Graduated medical school                                                                                                                    

   Before 1980                                                   17       8       13      8         10       7       5    12   8    18   4    4

   1980s                                                         47       40      41      8         41       15      26   19   45   36   20   22

   1990s                                                         23       32      25      40        30       56      24   12   32   21   43   63

   2000 or after                                                 12       20      17      40        16       19      45   58   12   25   26   11

  Practice location                                                                                                                           

   Central city                                                  27       44      16      56        39       70      19   23   29   43   74   96

   Suburb/small city/town                                        63       56      67      44        58       30      80   73   55   39   22   4

   Rural area                                                    11       0       17      0         3        0       0    0    16   18   4    0

  Continuing COPD education, yes                                 85       92      84      80        84       93      93   96   19   43   50   93

  Percentage of patients seen with COPD                                                                                                       

   51%--100%                                                     1        40      3       40        3        26      10   54   1    14   0    4

   31%--50%                                                      2        28      4       32        2        33      33   31   0    11   1    19

   11%--30%                                                      43       32      25      28        15       33      41   12   30   64   15   56

   1%--10%                                                       53       0       68      0         80       7       16   4    69   11   84   22

  Use term "COPD" when discussing diagnosis with patients, yes   96       96      100     100       99       100     92   89   84   82   93   100
  -------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Includes ambulatory care clinic

includes hospital-based clinic.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RS, respiratory specialist; NL, the Netherlands; SK, South Korea.

###### 

Tests typically used to establish a COPD diagnosis, by physician type: Continuing to Confront COPD International Survey, 2012--2013

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnostic test                                                           PCP (n=971)\   RS (n=336)\   *P*-value[\*](#tfn12-copd-10-039){ref-type="table-fn"}                  
                                                                            %              %                                                                                     
  ------------------------------------------------------------------------- -------------- ------------- -------------------------------------------------------- ----- ---- --- ---------
  Spirometry testing                                                        82             2             16                                                       100   0    0   \<0.001

   Prebronchodilator                                                        22                                                                                    15             

   Postbronchodilator                                                       7                                                                                     21             

   Both                                                                     69                                                                                    64             

  Peak expiratory flow                                                      55             29            16                                                       43    51   6   \<0.001

  Bronchodilator responsiveness                                             68             23            9                                                        80    19   2   \<0.001

  Oral corticosteroid responsiveness                                        38             52            9                                                        28    65   7   \<0.001

  Chest X-ray                                                               76             11            13                                                       89    10   2   \<0.001

  Blood test/oximetry                                                       45             32            23                                                       69    27   4   \<0.001

  CAT/CT/MRI scans                                                          21             53            25                                                       44    51   5   \<0.001

  Patient-reported outcomes (eg, dyspnea measure or COPD-assessment test)   67             28            5                                                        81    18   1   \<0.001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*-value comparing PCP to RS for responses of yes versus no/not available, adjusted for country and awareness of GOLD global strategy.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RS, respiratory specialist; CAT, computerized axial tomography; CT, computerized tomography; MRI, magnetic resonance imaging; GOLD, Global initiative for chronic Obstructive Lung Disease.

###### 

Key indicators for considering a COPD diagnosis: Continuing to Confront COPD International Survey, 2012--2013

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Key indicator                                                     PCP (n=971)\   RS (n=336)\   *P*-value[\*](#tfn14-copd-10-039){ref-type="table-fn"}
                                                                    %              %             
  ----------------------------------------------------------------- -------------- ------------- --------------------------------------------------------
  Chronic symptoms of airflow obstruction (ie, wheezing, dyspnea)   47             56            0.011

  Chronic cough with phlegm/sputum                                  39             44            0.050

  History of cigarette smoking/exposure to passive smoking          73             79            0.031

  Occupational exposure to smoke, fumes, or dust                    20             16            0.064

  Family history of emphysema/bronchitis/COPD                       14             13            0.778
  -------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*-value comparing PCP to RS, adjusted for country and awareness of GOLD global strategy. Percentages within a physician type will sum to greater than 100%; results from an open-ended question asking physicians to provide the top three most important factors in a patient's history when establishing a COPD diagnosis; no predefined list provided.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RS, respiratory specialist; GOLD, Global initiative for chronic Obstructive Lung Disease.
